Elpis Biopharmaceuticals and NCCS Partner on Next-Gen Cell Therapies for Solid Tumors

SINGAPORE and LEXINGTON, Mass. – July 27, 2025 – Elpis Biopharmaceuticals, a clinical-stage cell therapy company, has signed a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). This partnership aims to advance collaborative research and clinical trials for next-generation cell therapies targeting various solid tumors, including colorectal, pancreatic, and ovarian cancers.

This collaboration marks a significant step towards expanding CAR-T cell therapy beyond its current use in blood cancers. Elpis will contribute clinically validated technologies, such as multi-mechanism armor and bispecific targeting antibodies, as well as its rapid mRNA display discovery engine. These technologies are already being explored in Elpis’ global clinical trials (EPC-002 and EPC-003). Elpis also plans to establish a lab space at NCCS for integrated collaboration.

“By combining Elpis’s proprietary technology with NCCS’s clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients,” said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals.

NCCS will contribute its clinical research expertise and trial infrastructure to evaluate novel cell therapy candidates. “This collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes,” stated Professor Lim Soon Thye, CEO of NCCS.

The partnership will support the development of bispecific armored CAR-T cell therapies for solid tumors, with Elpis’s mRNA display technology also aiding NCCS in antibody discovery for novel targets. “This MOU represents an expansion of Elpis’s living drug strategy,” added Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals, aiming to make living drugs a reality for patients lacking effective treatment options.